Oral Delivery System: Amphotericin BiCo Therapeutics owns the worldwide exclusive rights to an oral delivery system: Amphotericin B (Amp B), for life-threatening infections. The drug delivery technology also has the potential to reprofile other drugs that would benefit from either oral administration and/or selective targeting of the lymphatic system. Amphotericin B, the gold standard for systemic antifungal drugs, is one example of a well established, highly efficacious systemic antifungal drug that has a 50 year history of intravenous therapy. Amphotericin B, formulated as liposomal Amphotericin (Ambisome®) for IV use, remains one of the most effective agents in the treatment of systemic fungal infections, yet no oral formulations are currently commercially available. Read More +
iCo-008 (also known as Bertilimumab or CAT-213) is a human monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, that acts as a messenger between the cells of the immune system.
We have partnered with Immune Pharmaceuticals. Immune has initiated a Ph 2, double-blind, placebo controlled study with iCo-008 in 90 patients with moderate-to-severe ulcerative colitis and Phase 2 results are expected in 2016. Immune has also initiated a Ph 2 study in Bullous Pemphigoid (BP), a rare auto-immune disease of the skin and expects data before the end of 2015.Eotaxin-1 is released by various cells, including eosinophils, epithelial cells, fibroblasts, endothelial cells, T-lymphocytes, monocytes and macrophages. During an allergic response the levels of eotaxin-1 are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders. This condition, known as eosinophilia, can occur in a number of disorders, such as allergic ocular disease of conjunctiva and cornea (conjunctivitis and keratoconjunctivitis), asthma, allergic rhinitis, atopic dermatitis, and other inflammatory disorders, such as inflammatory bowel disease and Crohn's disease. Read More +
iCo Therapeutics maintains rights to iCo-007, a novel second generation antisense C-Raf Kinase Inhibitor Program.